Clinical Trials

For the full list of oncology and hematology clinical trials and post authorization trials with active recruitment in 2021, please select the Clinical Trials Office tab below:
Clinical Trials Office
To view the list of early phase trials coordinated by our Early Clinical Drug Development Group in 2021 at the Research Unit for the Molecular Therapy of Cancer (UITM) – CaixaResearch, please click on the link below:
Early Clinical Drug Development

Clinical Trials Office

Oncology Clinical Trials (Phase 0, I + Baskets, II-III) with active recruitment 2021

Trial No. Clinical Trial Phase
CBGJ398X2204 A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy. II
GETNE-1206 (SEQTOR) Estudio abierto y aleatorizado para comparar la eficacia y la seguridad de everolimus seguido de quimioterapia con STZ-5FU tras la progresión o la secuencia invertida, quimioterapia con STZ-5FU seguida de everolimus tras la progresión, en tumores neuroendocrinos pancreáticos (TNEP) avanzados y progresivos (estudio SEQTOR) III
EORTC 1203-GITCG (INNOVATION) INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL. III
TTD-16-03 (AFEMA) Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. II
EF-27 (PANOVA-3) PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma. III
8951-CL-0301 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. III
MK-3475-811 Ensayo de fase III, aleatorizado y doble ciego para comparar trastuzumab más quimioterapia y pembrolizumab con trastuzumab más quimioterapia y placebo como tratamiento de primera línea en participantes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado con HER2 positivo (KEYNOTE 811). III
MK-3475-859 A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859). III
GEMCAD 1701 Estudio aleatorizado de fase II para evaluar la eficacia de FOLFIRI + panitumumab en el tratamiento en segunda línea de pacientes con cáncer colorrectal metastásico RAS no mutado que han recibido FOLFOX + panitumumab en primera línea de tratamiento. II
TTD-18-01 (CR- SEQUENCE) Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in treated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CRSEQUENCE. III
D6070C00005 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma. II
INCMGA0012-202 A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy. II
FiHM006 Ensayo fase II para evaluar la evolución de la carga de mutación de KRAS por biopsia líquida en pacientes con adenocarcinoma ductal pancreático resecable tratados con tratamiento neoadyuvante NALIRINOX. II
INCMGA0012-201 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma. II
XL184-311(COSMIC) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy. III
BGB-A317-306 A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. III
GETNE-T1812 (DUTHY) A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma-The DUTHY trial. II
INCB 54828-302 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302). III
ITM-LET-01 (COMPETE) A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). III
VHIO19001(MONEO) Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with respectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) – MONEO Study. II
GEMCAD 1703 (DUREC) Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial). II
EORTC 1607 “Open label first line, randomized phase II study of CisGem combined or not with pembrolizumab in patients with advanced or metastatic biliary tract cancer” II
QBGJ398-301 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial. III
GETNE-T1913 (NICE -NEC) A phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin. II
FGCL-3019-087 A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer. III
SMS-0472B (NEOFOX) A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer. II
CA209-8HW A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. III
NuTide:121 A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer. III
MS200647-0055 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer. II
D910CC00001(COLUMBIA-1) A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1). II
MK-7339-003( LYNK-003) A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003). III
MS100036-0020 A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the DNA-PK inhibitor M3814 in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer. I
MK-3475-966 A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma. III
CAAA601A22301 (NETTER-2) A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET. III
DZB-CS-301 A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications. II
J2G-MC-JZJB A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer LIBRETTO-531). III
4SC-202-3-2018 (MERKLIN 2) A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study. II
BOT112-02 Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastrooesophageal junction cancer. II
D-US-60010-001 (NAPAOLI3) An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas. III
CIBI308A301 (ORIENT-15) A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15). III
INCMGA0012-303 (POD1UM-303) A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2). III
MK-7902-014 A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pembrolizumab + Lenvatinib with Chemotherapy-Induction Followed by Pembrolizumab + Lenvatinib Compared with Chemotherapy as First-line Intervention in Participants with Metastatic Esophageal Carcinoma. III
MK-7902-015 A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Pembrolizumab + Lenvatinib + Chemotherapy Induction Therapy Followed by Pembrolizumab + Lenvatinib Compared with Chemotherapy in Participants with Previously Untreated Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction Adenocarcinoma. III
D910GC00001(MATTERHORN) A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (MATTERHORN). III
BNT122-01 A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection. II
CL3-95005-007 (SUNLIGHT) An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer. III
DS8201-A-U207 (DESTINY-CRC02) “A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)” II
2019-013-GLOB1 A GLOBAL, MULTICENTER, RANDOMIZED, PLACEBOCONTROLLED PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FRUQUINTINIB PLUS BEST SUPPORTIVE CARE TO PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2). III
G1T28-207(PRESERVE) A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer ( PRESERVE 1 ). III
IFOM-CPT005/2019/PO004 (PEGASUS) POST-SURGICAL LIQUID BIOPSY - GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS. II
ZWI-ZW25-203 A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers. II
YO42137 (SKYSCRAPER) A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA. III
CNIS793B12201 A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). II
DS8201-A-U306 A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen III
MK-7902-017 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed Through or Became Intolerant to Prior Treatment. III
ZWI-ZW25-301 A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) III
GO42661 A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER . II
SGNTUC-017 (MOUNTAINEER) MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer. II
2020-012-00EU1 An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe. II
GETNE-T1914 (CABATEN) Exploratory basket trial of cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system – The CABATEN study. II
AMCMEDONC17-010 (NAPAN) A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5 fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy. II
C4221015 (BREAKWATER) AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER (BREAKWATER). III
CA209-9N9 A study of Nivolumab in combination with Trametinib with or without Ipilimumab in participants with previously treated metastatic colorectal cancers. II
CITRIC Multicenter, open-label, randomized, 2-arm, phase II study to evaluate the efficacy and safety of cetuximab plus irinotecan rechallenge compared with investigator's choice of therapy in the third-line setting in ctDNA genomically selected patients with metastatic colorectal cancer (CITRIC Study). II
MK-1308A-008 Estudio de fase 2, multicéntrico y de varios grupos para evaluar pembrolizumab (MK-3475) o MK-1308A (coformulación de quavonlimab (MK-1308)/ pembrolizumab) en participantes con cáncer colorrectal en estadio IV con inestabilidad de microsatélites alta (MSI-H) o con defectos en la reparación de los errores de emparejamiento (dMMR): (MK-1308A-008). II
D910SC00001 (KUNLUN) A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma. III
BGB-A317-A1217-203 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 vCPS ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. II
MS202202-0002 A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR antibody targeting therapy due to MET amplification. II
MK-6482-015 A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET). II
HS-19-657 Estudio de fase III, aleatorizado, multicéntrico, controlado con tratamiento activo y abierto para evaluar la eficacia y seguridad de CAM2029 (octreótido depot S.C. ) vs. Octreótido LAR o Lanreótido ATG en pacientes con tumores neuroendocrinos gastro-pancreáticos. III
D8151C00001 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors. II
CLGK974X2101 A Phase I, open-label, dose escalation study of oral LGK974 in patients with melanoma and breast cancer. I
MCLA128-CL-01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors I
CA224-020 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody Nivolumab, BMS-936558) in Advanced Solid Tumors I
BAY 2757556 (LOXO-TRK-15002) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors I
MK-3475-158 Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158) I
CC-90010-ST-001 A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90010 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY NON-HODGKIN?S LYMPHOMAS I
CPDR001X2102 Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) . I
GO30103 (FELIX) "A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS" I
204691( ICOS ) A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors. I
RXDX-101-02 (STARTRK-2) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. I
1280.18 An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts. I
GO39374 A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER I
VHIO-PBF-999-01 "Phase I/Ib trial of single agent PBF-999 in solid tumour advanced cancer" I
CTNO155X2101 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors I
MK-4280-001 "A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors" I
PM14-A-001-17 Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors I
4010-01-001 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors I
W00101 IV 1 01 Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors International, multicenter, open label study. I
CNIR178X2201 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma. I
WO39608 (MORPHEO 1) A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER). I
CB103-C-101 A PHASE I/IIA, MULTI-CENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY WITH EXPANSION ARMS TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CB-103 ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL ALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY . I
CLHC165X2101 A Phase I/Ib, open-label, multi-center dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 in patients with advanced malignancies. I
BLU-667-1101 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. I
C0541001 A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS. I
BAY 1163877 / 19131 An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. I
64091742PCR2002 A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer. I
BO39610 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MORPHEUS-LUNG). I
AG270-C-001 A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP. I
1401-0001 An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours. I
GO39733 A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
XL184-021 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
BP40087 AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7122290, A FIBROBLAST ACTIVATION PROTEIN-a (FAP) TARGETED 4-1BB LIGAND (CD137L), WITH OR WITHOUT OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB FOLLOWED BY TUMOR SPECIFIC EXPANSION COHORT(S). I
GO39932 "A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer" I
CO40115 "A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MORPHEUS TNBC)" I
CA022-001 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. I
MEN1611-01(B PRECISE 01) OPEN-LABEL, MULTICENTER, PHASE IB DOSE-ESCALATION STUDY OF MEN1611, A PI3K INHIBITOR COMBINED WITH TRASTUZUMAB ± FULVESTRANT, IN SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADVANCED) OR METASTATIC (A/M) BREAST CANCER PROGRESSED TO ANTI-HER2 BASED THERAPY . I
LOXO-EXT-17005 A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers. I
BP40234 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
LOXO-RET-17001 "A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medularry Thyroid Cancer, and Other Tunors with Increased RET Activity". I
GCT1029-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors. I
BGB-290-103 A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors. I
MCLA-158-CL01 Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors. I
64619178EDI1001 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
CC-90011-ST-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90011 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN’S LYMPHOMAS. I
IOV-COM-202 A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors. I
J1F-MC-JZFA A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors. I
VHIO17002 (MO39164) Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours. I
D8530C00001 A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast CancerA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer. I
C2321001 A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL). I
GEIS 58 (OLATRASTS) "Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado" I
CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H). I
CO40939 A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
CADPT01A12101C A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer. I
YO40482 A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER. I
MK-7339-002 A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer. I
SGNTV-001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. I
61186372EDI1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer. I
B9991032 A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS. I
ICO-VCN-H&N-2018 A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck. I
WO39613 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC). I
GCT1046-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors. I
BP40657-III A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER III
CP-MGD013-01 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms. I
ZEN003694-004 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer. I
D7980C00001 (MEDI5752) A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors. I
20140318 (MASTERKEY-318) A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318). I
NBTXR3-102 ESTUDIO DE FASE I DE AUMENTO ESCALONADO/AMPLIACIÓN DE LA DOSIS DE NBTXR3 ACTIVADO MEDIANTE RADIOTERAPIA DE INTENSIDAD MODULADA EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS LOCALMENTE AVANZADO EN LA CAVIDAD BUCAL O LA OROFARINGE. I
SC103 A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. I
XL184-021 (PULMON) A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
BP41054 AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED AND/OR METASTATIC MELANOMA. I
208850 (STING) A Phase I First Time in Human Open Label Study of GSK3745417 administered with and without Anticancer Agents in Participants with Advanced Solid Tumors. I
TCD14678 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with cemiplimab in adult patients with advanced solid tumors. I
CLXH254X2102 A Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma. I
CTNO155B12101 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies. I
CP-MGC018-01 A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation of Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) alone and in combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors. I
M19-037 A Phase 1, Multi-Center, Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Pharmacokinetics of ABBV-927 and ABBV-368 with and without ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumor. I
LOXO-RET-18037 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201). I
1336-0011 An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors. I
CL1-95012-001 “Estudio de primera administración en humanos de fase I/II, abierto, multicéntrico, de escalada de dosis y expansión con PRS-344/S095012 en pacientes con tumores sólidos” I
1426-0001 Phase I, first in human trial evaluating BI 1387446 alone and in combination with BI 754091 in solid tumors. I
ASTX029-01 A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors. I
SGN228-001 A phase 1 study of SGN-CD228A in subjects with select advanced solid tumors. I
42756493CAN2002/ODIN (RAGNAR) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations. I
NP40435 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7121661, A PD-1/TIM-3 BISPECIFIC NTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
CNTO1959COR1001 A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis. I
20180290 A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects with MUC17-Positive Gastric and Gastroesophageal Junction Cancer. I
NP41300 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
CNIZ985B12101 A Phase I/Ib Study of Subcutaneous Recombinant NIZ985 ((het-IL-15) (IL-15/sIL-15Rα)) in combination with Spartalizumab in adults with check point inhibitor (CPI) relapsed advanced malignancies. I
SOLTI-1507 (IPATHER) A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PI3KCA-mutant, HER2-positive locally advanced or metastatic breast cancer (IPATHER) I
INCB 54828-207 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). I
2455-002 An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma. I
WP41188 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7296682, A CD25-TARGETING, T-REGULATORY CELL DEPLETING ANTIBODY IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS I
SL01-DEL-101 Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas. I
WP41377 A FIRST IN HUMAN, OPEN LABEL, DOSE ESCALATION PHASE I STUDY EVALUATING SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ACTIVITY PROFILE OF SINGLE AGENT RO7119929 (TLR7 AGONIST 4 ASIP) ADMINISTERED ORALLY TO PARTICIPANTS WITH UNRESECTABLE ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA, BILIARY TRACT CANCER, OR SOLID TUMORS WITH PREDOMINANTLY HEPATIC METASTASES. I
CKAZ954A12101 A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors. I
EOGBM1-18 A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma (Rosalie study). I
AFM24-101 A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers. I
BAY88-8223/19781 An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer. I
CV-8102-008 Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. I
1412-0001 A first-in-human phase Ia/b, open label, multicentre, dose escalation study of BI 905711 in patients with advanced gastrointestinal cancers. I
IMC-C103C-101 A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer. I
J2J-MC-JZLA A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer. I
208471 A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer. I
CC-90011-SCLC-001 A PHASE 1B, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-90011 GIVEN IN COMBINATION WITH CISPLATIN AND ETOPOSIDE TO SUBJECTS WITH FIRST LINE, EXTENSIVE STAGE SMALL CELL LUNG CANCER. I
2SMALL Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy. I
GCT1044-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumours. I
EOADR1-19 (SPENCER) A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma. I
GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS. I
CO41863 A PHASE Ib/II, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTANSINE (T-DM1) IN PREVIOUSLY TREATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS. I
CC-90010-GBM-002 A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90010 IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIATION THERAPY IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. I
208750 Seguimiento a largo plazo de los participantes expuestos a GSK3377794 (NY-ESO-1c259 T), un receptor de linfocitos T específicos de NY-ESO-1 modificado genéticamente. I
BP41628 AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSEESCALATION AND EXTENSION, PHASE IA/IB STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
BNT411-01 Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC). I
CO41792 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. I
1438-0001 A First–in-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3. I
M19-611 A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer. I
4020-01-001 (AMBER) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER). I
ICT01-101 A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study). I
DCC-3014-01-001 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors. I
D6770C00001 Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumors. I
Uni-Koeln-1784 (EATON) An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generationEGFR TKI therapy. I
DEBIO 1143-106-II SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. I
70218902EDI1001 A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors. I
Debio 0123-101 A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors. I
20180292 A Global Phase 1 Study Evaluating the Safety,Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. I
CBLZ945X2101 A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors. I
MEN1611-02 (C-PRECISE-01) OPEN-LABEL,MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CAMUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING REGIMENS. I
V937-013 Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors. I
GO41751 A PHASE I, OPEN-LABEL, DOSE-ESCALATION PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER. I
LOXO-IDH-20002 A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 R132 Mutations. I
GCT1042-01 A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects with Malignant Solid Tumors. I
NOCANTHER A feasibility clinical investigation of intratumoral injection of magnetic nanoparticles associated to hyperthermia treatment in locally advanced pancreatic cancer. I
D967VC00001(DESTINY-PanTumor02) Phase 2, Multicentre, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors . I
PM1183-A-017-20 An Open-Label, Multicenter, Pharmacokinetic Study of Lurbinectedin in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment. I
AFM24-101-II A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers. I
D967MC00001 (DESTINY) Phase II, multicenter, open-label study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of unresectable and/or metastatic solid tumors harboring HER2 activating mutations regardless of tumor histology. I
CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers. I
SGNTGT-001 A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies. I
73841937NSC1001 An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer. I
D967LC00001(DESTINY 3) A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03). I
213152 A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer with Disease Progression or Recurrence Following Treatment with a Platinun agent. I
BT8009-100 (BICYCLE) Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies. I
ACT16432 Open-label, multi-cohort, Phase 2 trial, evaluating the efficacy and safety of SAR408701 in patients with CEACAM5-positive advanced solid tumors. I
CADPT01C12101 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer. I
CJDQ443A12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. I
TAS-120-202 A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations. I
GO42144 A PHASE I DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC 6036 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION. I
ABT-C11-2020 A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. I
BP42169 AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7293583, A TYRP1-TARGETING CD3 T-CELL ENGAGER, IN PARTICIPANTS WITH METASTATIC MELANOMA. I
BP42595 AN OPEN-LABEL, MULTICENTER PHASE 1b STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7296682 IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
DZB-CS-202 (BASILEA) Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03). I
SGNB6A-001 A Phase 1 Study of SGN-B6A in Advanced Solid Tumors. I
CA030-001 A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors. II
MS200647_0046 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer. I
R6569-ONC-1933 A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies. I
D9720C00001(PETRA) A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5305 monotherapy and in combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies. I
BP42675 AN OPEN LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF CIBISATAMAB IN COMBINATION WITH RO7122290, A FIBROBLAST ACTIVATION PROTEIN A (FAP) TARGETED 4 1BB LIGAND (CD137L), WITH OBINUTUZUMAB PRE TREATMENT, IN PARTICIPANTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
OMO-103-01(OMOMYC) A Phase 1/2 Study to evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the Myc Inhibitor OMO-103 administered intravenously in Patients with Advanced Solid Tumours. I
2020-306-GLOB2 MULTICENTER, OPEN-LABEL PHASE I STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-306 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS. WITH IDH MUTATIONS I
CTL-002-001 A PHASE I, FIRST IN HUMAN, TWO PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT-INHIBITOR IN SUBJECTS WITH ADVANCED STAGE, RELAPSED/REFRACTORY SOLID TUMORS. I
FS222-19101 (F-STAR) A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects with Advanced Malignancies. I
CDKY709A12101C A phase I, open-label, multi-center, study of DKY709 as a single agent and in combination with spartalizumab in patients with advanced solid tumors, I
1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit. I
20180143 A Phase 1 Study to Evaluate Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors. I
CTMX-M-2029-001 (PROCLAIM-CX-2029) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). I
CO42867 Phase 1b/II umbrella, adaptive design study The first cohort of the new Breast Cancer study will target 2L or 3L metastatic or inoperable locally advanced ER+ Breast Cancer patients who had disease progression during or following treatment with a CDK4/6i. I
AGI-134.FIM.101 A PHASE I/IIA, MULTICENTRE, TWO-PARTS, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF AGI-134 GIVEN IN UNRESECTABLE/METASTATIC SOLID TUMOURS I
VHIO20001 (NEXTGEN-TIL-ACT) A Phase I study to assess the safety and tolerability of ex vivo neoantigen-selected Tumor-infiltrating Lymphocytes (TILs) in advanced epithelial tumors and refractory melanoma. I
1472-0001 A Phase Ia/Ib, open-label, multicentredose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumoursexpressing KRAS G12C mutation. I
20180144 A Phase 1 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients with Advanced Solid Tumors. I
BNT151-01 Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT151 as a monotherapy and in combination with other anti-cancer agents in patients with solid tumors. I
20160323 (AMG757) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer. I
SOLTI-1904 (ACROPOLI) EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial). I
D933IC00001(MAGELLAN) A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN). I
D9570C00001 A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, anti-TIM-3 and anti PD-1 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors . I
SGNSTNV-001 A Phase 1 Study of SGN-STNV in Advanced Solid Tumors. I
WP42627 AN OPEN LABEL, MULTICENTER, DOSE-ESCALATION AND EXPANSION, PHASE I STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND ANTI-TUMOR ACTIVITY OF RO7300490, A FIBROBLAST ACTIVATION PROTEIN-á (FAP) TARGETED CD40 AGONIST, AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
NLM-2020-01(NELUM-NLM) Phase Ib/IIa Study to evaluate safety and efficacy of Priming Treatment with the Hedgehog Inhibitor NLM-001 Prior to Chemotherapy (Gemcitabine and Nab-Paclitaxel) plus AGEN 1884 as First Line treatment in Patients with Advanced Pancreatic Cancer. I
Sym021-02 An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD-1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies. I
M20-111 A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 monotherapy and combined with docetaxel in adult subjects with relapsed and refractory solid tumors. I
BO41932 TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL. I
ACT16845 Estudio de fase 2 no aleatorizado, abierto, multicéntrico y de múltiples cohortes que evalúa el beneficio clínico de SAR444245 (THOR-707) en combinación con cemiplimab para el tratamiento de participantes con cáncer avanzado de piel irresecable o metastásico I
MK-6482-016 An Open-label, Multicenter, Phase 2 Study of Pembrolizumab Plus Lenvatinib in Combination With MK-6482 in Multiple Solid Tumors. I
CIAG933A12101 “Estudio de fase I, multicéntrico y abierto de IAG933 oral en pacientes adultos con mesotelioma avanzado y otros tumores sólidos” I
CO42800 "A PHASE IB, OPEN-LABEL, DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF INAVOLISIB IN COMBINATION WITH PACLITAXEL AND WITH OR WITHOUT TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS". I
CAN04CLIN003 A PHASE 1B DOSE ESCALATION AND EXPANSION STUDY OF CAN04, A MONOCLONAL ANTIBODY TARGETING IL1RAP, IN COMBINATION WITH MODIFIED FOLFIRINOX IN SUBJECTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA. I
MK-3475-B98 (KEYNOTE-B98) A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy. I
D9950C00001 A Phase I First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvalumab (MEDI4736) in Participants With Advanced Solid Tumours. I
WO42758 (INTRINSIC) A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC). I
DS1062-A-U102 (Tropion- Lung02) “Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Subjects with Advanced or Metastatic NonSmall Cell Lung Cancer (Tropion-Lung02)” I
EZH-108 A PHASE I, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADYSTATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF AZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES. I
20190136 A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects with Advanced Solid Tumors. I
78306358STM1001 A Phase 1, First-in-Human, Dose Escalation Study of JNJ-78306358 in Participants with Advanced Stage Solid Tumors. I
CAN04CLIN004 Phase 1/2 study of CAN04 (a fully humanized monoclonal antibody against L1RAP) in combination with different chemotherapy regimens in patients with advanced solid tumors. I
ANV419-001 ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors. I
1463-0001 Phase I dose-finding study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers. I
INCB 106385-102 A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors. I
GEIS-67 (SeliSarc) Ensayo clínico aleatorizado fase I/II de selinexor más gemcitabina en determinados sarcomas de partes blandas y osteosarcomas avanzados. I
M20-732 A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination with Modified FOLFIRINOX (mFFX) With or Without Budigalimab compared to mFFX in Subjects with Untreated Metastatic Pancreatic Adenocarcinoma. I
AFM24-102 A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR expressing Cancers I
STRO-002-GM1 A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers. I
20140318 (MASTERKEY-318) A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination with Systemic Pembrolizumab (MASTERKEY-318). I
1403-0001 A phase Ia/Ib, open labeA phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumorsl, multicenter, dose-escalation stud I
D9720C00001(PETRA) A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5305 monotherapy and in combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies. I
D967LC00001(DESTINY 3) A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03). II
MS200095-0022 Ensayo de fase II de un único grupo para investigar tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de MET (METex14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino. II
GL0817-01 "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity" II
BGBC008 A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the LungA Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung. II
BO29554 (BFAST) A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON−SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL). II
MK-3475-495 A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475,SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT). II
MK-3475-689 (SCH 9000475) A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC). III
ETOP12-17 (ALERT-lung ) A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC. II
GO40241 A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON−SMALL CELL LUNG CANCER. III
BO40336 (ALINA) A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ³ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA INASE-POSITIVE NON-SMALL CELL LUNG CANCER. III
GECP 17/02 (REPLAY) A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer. II
Brigatinib-3001 A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib XALKORI®). III
GECP17/04 (THOMAS) An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations. II
ISA101b-HN-01-17 A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC). II
D933QC00001(ADRIATIC) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC). III
TACTI-002 (P015) TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist). II
205801 (ENTREE LUNG) A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants. II
ETOP 13-18 (BEAT-meso) Ensayo clínico Fase III multicéntrico aleatorizado que compara atezolizumab más bevacizumab y la quimioterapia habitual con bevacizumab y la quimioterapia habitual como tratamiento de primera línea para el mesotelioma pleural maligno III
KO-TIP-007 The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). II
MK-7902-008 A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (anti-PD-1/PD-L1 inhibitor) (LEAP-008). III
MK-3475-867 A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867). III
M14-239 (LUMINOSITY) Estudio de fase II abierto para evaluar la seguridad y la eficacia de telisotuzumab vedotina (ABBV-399) en pacientes con cáncer de pulmón no microcítico c-Met+ tratado previamente. II
ARRAY-818-202 A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer. II
GECP 18/02 (NADIM II) A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemotherapy alone for the treatment of locally advanced and potentially resectable nonsmall cell lung cancer (NSCLC) patients” NADIM II. II
MS200647-0005 A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer. III
MS200095-0031(INSIGHT-31) A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy. II
MM-398-01-03-04-III (RESILIENT) RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy. III
TPX-0005-01(TRIDENT-1) A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). II
16-214-05 A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors. II
MK-7902-010 A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010). III
TAK-788-3001 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations. III
MK-1454-002 A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy. II
GO41767 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER III
1740-HNCG RANDOMIZED PHASE II STUDY OF CISPLATIN PLUS RADIOTHERAPY VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT DURVALUMAB VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT TREMELIMUMAB AND DURVALUMAB IN INTERMEDIATE RISK HPV-POSITIVE LOCOREGIONALLY ADVANCED OROPHARYNGEAL SQUAMOUS CELL CANCER (LA-OSCC). II
GO41717 A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER. III
209229 (INDUCE 3) A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma . II
CC-90011-ST-002 A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers. I
MK-7339-012 A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC). III
MK-7902-009 A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009). II
GO41836 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAPY IN PATIENTS WHO ARE ctDNA POSITIVE AFTER SURGICAL RESECTION OF STAGE II-III NON-SMALL CELL LUNG CANCER. II
GECP 19/01 (CUBIK) CLINICAL UTILITY OF LIQUID BIOPSY AS A TOOL TO ASSESS THE EVOLUTION OF BRIGATINIB TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EML4-ALK TRANSLOCATION: AN EXPLORATORY STUDY II
D7310C00001(INTERLINK-1) A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor. III
213410 (COSTAR) A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY. II
MK-3475-671 A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC). III
MK-3475-A86 A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous embrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer. III
GO41854 “ESTUDIO FASE III, ABIERTO, ALEATORIZADO DE ATEZOLIZUMAB Y TIRAGOLUMAB EN COMPARACIÓN CON DURVALUMAB EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO LOCALMENTE AVANZADO EN ESTADIO III IRRESECABLE QUE NO HAN PRESENTADO PROGRESIÓN DESPUÉS DE QUIMIORRADIOTERAPIA CON PLATINO CONCOMITANTE (SKYSCRAPER-03)” III
ACT16849 Estudio de fase 2 no aleatorizado, abierto, de múltiples cohortes, multicéntrico, para evaluar el beneficio clínico de SAR444245 (THOR-707) combinado con otras terapias anticancerígenas para el tratamiento de participantes con cáncer de pulmón o mesotelioma pleural II
CINC280I12201 A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1≥ 50%. II
BO42864 (AcceleRET) A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non- Small Cell Lung Cancer. III
D4194C00009 (DUART) A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy (DUART). II
DS8201-A-U206 Phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-mutated metastatic Non-Small Cell Lung Cancer clinical trial . II
Debio 1143-SCCHN-301 (TrilynX) A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). III
GO41892 (CONTACT 01) A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH AN ANTI-PD-L1/PD-1 ANTIBODY AND PLATINUM-CONTAINING CHEMOTHERAPY. III
CINC280J12201 A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as first line treatment for locally advanced or metastatic non-small cell lung cancer patients with MET exon 14 skipping mutations. II
IRFMN-NSCLC-8187 / BRIDGE MedOPP352 Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volume stage III NSCLC. II
213400 (ZEAL-1) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer. III
D910LC00001 (MERMAID-1) A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1). III
20190009 A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C. III
849-007 (KRYSTAL-07) A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. II
DS1062-A-U202 (TROPION-LUNG05) Phase 2, Multicenter, Randomized Study of DS-1062a in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations and Previously Treated with Kinase Inhibitor Therapy and Platinum-based Chemotherapy with or without Prior Immunotherapy. II
MK-7339-013 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC). III
CA224-104 A Phase II Randomized Double-blind Study of Nivolumab plus Relatlimab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC). II
GO42501 EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB, WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY, IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON-SMALL CELL LUNG CANCER II
HR-BLTN-III-NSCLC A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy. III
GECP 20/05 CA209-7YC (NADIM-ADJUVANT) A PHASE III CLINICAL TRIAL OF ADJUVANT CHEMOTHERAPY VS CHEMO-IMMUNOTHERAPY FOR STAGE IB-IIIA COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS. III
73841937NSC3003 A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(MARIPOSA). III
516-005 (SAPPHIRE) A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE). III
209227 (INDUCE 4) A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy or First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. III
61186372NSC3001 (PAPILLON) A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. III
CA209-7H4 (NIPU) Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma. II
D516AC00001 (Neo-Adaura) A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA). III
ETOP 15-19 ABC-lung A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant non-small cell lung carcinoma with acquired resistance. II
CA001-050 A randomized study of BMS-986012 in combination with Carboplatin, Etoposide and Nivolumab in participants with extensive-stage Small Cell Lung Cancer. II
D910MC00001(MERMAID-2) A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2). III
ETOP 14-18 CHESS A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-etastatic nonsmall cell lung cancer. II
U31402-A-U201 (HERTHENA-Lung01) A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFRmutated Non-Small Cell Lung Cancer (NSCLC) (HERTHENA-Lung01 ) II
DS1062-A-U301(TROPION-LUNG01) PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01). III
MS201923-0050 (DRIVER250) A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum resistant small-cell lung cancer. II
CINC280L12301 "A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic Non‑ Small Cell Lung Cancer (NSCLC) MET amplified Harboring EGFR activating mutations,T790M negative who have progressed on prior EGFR-Tyrosine Kinase Inhibitor (EGFR‑ TKI) therapy. III
D6132C00001 (TAZMAN) A Phase II Multicenter, Open-Label, Single Arm Study to determine the Efficacy , Safety and Tolerability of AZ2811 and Durvalumab Combination as Maintenance theray after induction with platinum -based Chemotherapy combined with Durvalumab , for first line treatment of patients with extensive Stage Small Cell Lung Cancer. II
GECP 20-01 - ML42249 (Neo-DIANA) A PHASE II TRIAL OF NEOADJUVANT TREATMENT CARBOPLATIN-PEMETREXED-BEVACIZUMAB PLUS ATEZOLIZUMAB FOR THE TREATMENT OF LOCALLY ADVANCED AND POTENTIALLY RESECTABLE NSCLC PATIENTS WITH EGFR MUTATIONS. II
Gortec 2018-01 (NIVO POST-OP) A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN). III
J2G-MC-JZJX A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC. III
MK-3475-B99 A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive Stage Small Cell Lung Cancer. II
20190442 A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotosarib) for the Treatment of Subjects in Selected European Countries with Previously Treated Locally Advanced and Unresectable or Metastatic Non-small Cell Lung Cancer with KRAS p.G12C Mutation. III
GCT1046-04 ‘A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor’ II
GECP 20/09 (BIMES) A PHASE II SINGLE ARM CLINICAL TRIAL ASSESSING THE EFFICACY AND SAFETY OF BINTRAFUSP ALFA (M7824) IN PREVIOUSLY TREATED ADVANCED MALIGNANT PLEURAL MESOTHELIOMA. II
BGB-A317-A1217-302 A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer. III
TTCC 2019-01 (NIVOTAX) Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX). II
ISG-GEIS 10-01(GEIS 25 ) SARCOMAS DE PARTES BLANDAS LOCALIZADOS DE ALTO RIESGO DE EXTREMIDADES Y PARED DE TRONCO EN ADULTOS: UN ENFOQUE INTEGRADOR QUE INCLUYE QUIMIOTERAPIA ESTÁNDAR VS HISTOTIPO-DIRIGIDA NEOADYUVANTE. III
GETUG-AFU 23 (PEACE-2) A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse. III
TRASTS-I (GEIS 37) Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos I
EORTC STUDY 62113-55115 A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment II
TRASTS-II (GEIS 37) Ensayo clinico Fase I-II, abierto, prospectivo y muticéntrico, que explora la combinación de Trabectedina y Radioterapia en pacientes con Sarcoma de tejidos Blandos II
42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations II
RG-13-277 An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. II
SSGXXII (GEIS 42) Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study III
MK-3475-365 Ensayo de fase Ib/II de tratamientos combinados con pembrolizumab (MK-3475) en el cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-365) II
010580QM (CALYPSO) MEDI4736 combinations in metastatic renal cell carcinoma (CALYPSO) II
ARO 012 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene III
GEIS-52 Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas. II
GEIS 36 (COSYMO) A phase 2, single arm, multi center trial evaluating the efficacy of the COmbination of Sirolimus and cYclophosphamide in metastatic or unresectable Myxoid liposarcoma and chOndrosarcoma. II
C3441021 (TALAPRO 2) A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. III
D933SC00001 (Nile) Ensayo fase III, aleatorizado, abierto, controlado, multicéntrico, internacional de durvalumab en combinación con el tratamiento estándar con quimioterapia y durvalumab en combinación con tremelimumab y el tratamiento estándar con quimioterapia frente al tratamiento estándar con quimioterapia solo, en primera línea en pacientes con cáncer urotelial localmente avanzado irresecable o metastásico. III
1333-GUCG (PEACE III) A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. III
I3Y-MC-JPCM A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer. II
SUNNIFORECAST A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma. II
D933RC00001 (NIAGARA) A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA). III
MK-7339-010 A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010). III
CA045009 A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible. III
J1S-MC-JV02 A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma. II
J1S-MC-JV01 A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor. II
MIN-003-1806 (CLINGLIO) A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment. II
AG881-C-004 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of AG-881 in Subjects with  Residual/Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation. III
GEIS 41 A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) . II
CNIO-CP-2019-01 (BioChiP) A phase II, open-label, biomarker-guided study of carboplatin efficacy in pre-treated metastatic castration- resistant prostate cancer (CRPC). II
ADP-0044-002 (SPEARHEAD) A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma. II
XL184-313 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk. III
DZB-CS-201 (FIDES-2) An open label multi-cohort Phase 1/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-2). II
MK-6482-005 An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies. III
SGN22E-003 (EV-302) An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. III
CA209-914 A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. III
QBGJ398-302 (PROOF302) Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302). III
WO41994 (CONTACT-03) A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED. DIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT III
D5339C00001(PLANETTE) A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE). II
MK-3475-03A A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A. II
MK-3475-03B Estudio de fase 1b/2 de terapias inmunitarias y dirigidas combinadas en participantes con carcinoma renal (CR) (U03): subestudio 03B. II
D8731C00002 (AARDVARC) A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC). II
MK-3475-B61 A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61) II
TAS-120-203 A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma. II
XL184-315 (CONTACT-02) A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer. III
MEDOPP234 (ZZ-FIRST) Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer. II
CAAA617B12302 PSMAfore: Estudio de fase III, multicéntrico, aleatorizado y abierto en el que se compara 177Lu-PSMA-617 frente a un cambio de terapia dirigida al receptor de andrógenos en el tratamiento de hombres con cáncer de próstata metastásico progresivo resistente a la castración que no hayan recibido taxanos. III
IMMU-132-13 (TROPICS-04) Phase III Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer. III
I3Y-MC-JPCY A Phase 2 Study of Abemaciclib in Metastatic Castration- Resistant Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and Taxane-based Chemotherapy. II
GEIS-75 Phase II multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas (SYNERGIAS). II
BO42843 A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA-POSITIVE FOLLOWING CYSTECTOMY. III
D910PC00001 (VOLGA) A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA). III
C3441052 (talapro-3) PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER. III
D5086C00001(SAMETA) A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC) III
MK-6482-011 An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy. III
RAIN-3201 “A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma” III
MK-3475-B15 A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304). III
EUOG-2016-003 (URANUS) Neo-adjuvant versus Adjuvant chemotherapy in Upper Tract Urothelial Carcinoma: A feasibility phase II randomized clinical trial (“URANUS”). II
PUMA NER-5201 An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification. I
SOLTI-1303 (PATRICIA) PATRICIA: Ensayo clínico fase II de la combinación de palbociclib y trastuzumab con o sin letrozol en pacientes postmenopáusicas con cáncer de mama localmente avanzado o metastásico HER2-positivo previamente tratado II
MO29406 A SINGLE-ARM OPEN-LABEL MULTI-CENTRE EXTENSION STUDY OF PERTUZUMAB ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A HOFFMANN-LA ROCHE-SPONSORED PERTUZUMAB STUDY III
GEICAM 2015-06 (COMETA) A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast Study). II
AFT-38 (PATINA) "Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2 + tratamiento endocrino frente a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de mama metastásico positivo para receptores hormonales (HR+)/positivo para HER2 " III
D0816C00014 (OReO) A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO). III
MO39193 (IMPASSION) A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALLY ADVANCED OR METASTATIC) TRIPLE-NEGATIVE BREAST CANCER. III
C-145-04 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma. II
MK-3475-756 A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756) . III
ENGOT-Cx10/GEICO 68-C/ BEAT cc A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix. III
CA045001/18-214-08 A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma. III
ENGOT OV41 GEICO- 69-O(ANITA) A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months. III
MK-3475-630 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma(LA cSCC) (KEYNOTE-630).. III
MedOPP168 (OPHELIA) Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients .– The OPHELIA Study – II
SGNLVA-002 Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer. II
SOLTI-1503 (PROMETEO) Combination of Talimogene Laherparepvec with Atezolizumab in residual breast cancer following standard neoadjuvant multi-agent chemotherapy (PROMETEO TRIAL). 0
BGOG-EN5/ENGOT-EN5/SIENDO An Investigator-Sponsored Randomized Phase III Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer. III
R2810-ONC-1540 (REGENERON) A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. II
GO40987 A PHASE I, MULTICENTER, OPEN-LABEL PREOPERATIVE SHORT-TERM WINDOW STUDY OF GDC-9545 IN POSTMENOPAUSAL WOMEN WITH STAGE I-III OPERABLE, ESTROGEN RECEPTOR-POSITIVE BREAST CANCER. I
IRFMN-EN-7556 (AtTEnd) PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER. III
GEICO 78-C (ATOMICC) A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation. II
MedOPP068 (PALMIRA) International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in hormone receptor-positive/HER2-negative Advanced Breast Cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment. (PALMIRA). II
D3614C00001 (CAPITELLO) DB, Rando study assigned the efficacy and Safety of Capivasertib+pacli VS placebo+pacli as 1L for pa with histologically confirmed , locally advanced (inoparable)or M1 TNBC. III
CLEE011O12301C (TRIO033 NATALEE) A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]:NATALEE). III
1612-MG(EORTC) Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation : an EORTC randomized phase II study (EBIN). II
GEM-1802 ( ​EBRAIN-MEL) Phase II, multicenter clinical trial to evaluate the activity of encorafenib and binimetinib administered before local treatment in patients with BRAF mutant melanoma metastatic to the brain. II
ACT16105 An open-label randomized Phase 2 trial of SAR439859, versus endocrine monotherapy as per physician’s choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies. II
IBCSG 59-19 / BIG 18-02 (POLAR) A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer. III
IMMU-132-09 Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens. III
ODO-TE-B202 (CONTESSA 3) A multicenter, phase II, study of Tesetaxel plus three diferent PD_L-1 inhibitors in patients with triple negative , locally advanced or metastasic breast cancer and tesetaxel monotherapy in elderly patients with HER2 negative , LAMBC. II
MK-7339-009 An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009). II
APX005M-010 A Phase II Multicenter, Open-label Study in Two Parallel-Groups to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M in Adults with Immunotherapy Naive Unresectable or Metastatic Melanoma. II
TAS-120-201 A Phase 2 Study of TAS-120 in Metastatic Breast Cancer Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications. II
SOLTI-1802 (ONAWA) A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women with Hormone Receptor-Positive and HER2-negative Breast Cancer. 0
ANZ 1601/BIG 16-02 A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer. III
SOLTI-1502 (ARIANNA) TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER. II
CA209-7A8 “Randomized, Non-comparative Neoadjuvant Phase II Study in Postmenopausal Women with Stage II-III, ER+/HER2- Breast Cancer with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7A8)”. II
20180115 (MASTERKEY-115) Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With nresectable/Metastatic Stage IIIB-IVM1c Melanoma Who Have Progressed on Prior Anti-PD-1 Based Therapy. II
CA209-7FL A Randomized, multicenter, double-lbind, placebo -controlled phase 3 study of nivolumab VS placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine Therapy in the treatment of high-risk, stage II-III estrogen receptro-positive (ER+), human epidermal growth factor receptro 2- negative (HER2-) breast cancer. III
R2810-ONC-1788 A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma. III
NSABP B-59/GBG 96 (GeparDouze) A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo. III
SOLTI-1716 (TATEN) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor treatment. II
D3615C00001 (CAPITELLO-291) A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291). III
SOLTI-1804 (HER2PREDICT) HER2-PREDICT: TRANSLATIONAL STUDY OF TUMOR SAMPLES FROM DS8201-A-U301 AND DS8201-A-U302 TRIALS. II
WO41554 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER. III
AGO-OVAR 2.29 /ENGOT OV-34 /GEICO 65-O Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomized Phase III trial . III
QPT-ORE-005 (FLORA-5) A phase 3, double-blind, placebo-controlled, multicenter clinical study comparing chemo-immunotherapy (paclitaxel-carboplatin-oregovomab) versus chemotherapy (paclitaxel-carboplatin-placebo) in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma III
SGNTV-002 Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen. II
D8530C00002 (SERENA-2) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer. II
ZWI-ZW25-202 Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant. II
EORTC-1745-ETF-BCG(APPALACHES) A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES). II
MK-3475-A18 A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11). III
SGNTUC-016 Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02). III
MedOPP190 (LUZERN) Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancers with either Germline BRCA-mutated or Germinal BRCA-wild-type and Homologous Recombination Deficiency (HRD). II
D6018C00004 (DUETTE) A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatment, II
IMGN853-0417 (SORAYA) SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. III
GO40558 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA. II
EDO-S101-1002 “Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in- Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors” II
UC-0140/1812 (DOLAF) DOLAF- An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib. II
MO42319 (KATE-3) A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE AND PD-L1 POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY . III
D8532C00001(SERENA-4) A Randomised, Multicentre, Double-Blind, Phase 3 Study of AZD9833 (An Oral SERD) plus Palbociclib plus Anastrozole Placebo versus Anastrozole plus Palbociclib plus AZD9833 Placebo for the Treatment of Patients with Estrogen Receptor-ositive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. III
RPL-002-18 (CERPASS) A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma. II
D9670C00001 (Destiny06) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06). III
SOLTI-1718 (NEREA) Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial). II
D601HC00002 (ADAGIO) A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrentor Persistent Uterine Serous Carcinoma (ADAGIO). II
20-214-29/CA045-022 A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12). III
SOLTI-1907 (ATREZZO) A Phase II with 2 parallel cohorts clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positive advanced/metastatic breast cancer – ATREZZO Study. II
AL-TNBC-01 (TENACITY) TENACITY: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer . II
MK-3475-B21 ( KEYNOTE-B21 / ENGOT –en11) Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without (Chemo)Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent. III
ML42502( Estudio PHaTiMa) TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER. III
CTMX-2009-002 A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002) II
BO41843 A PHASE III RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER. III
I3Y-MC-JPCW eMonarcHER: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se evalúa abemaciclib con la hormonoterapia adyuvante de referencia en participantes con cáncer de mama HR+, HER-2+, de riesgo alto y con afectación ganglionar, que hayan completado un tratamiento adyuvante dirigido al HER2. III
4010-03-001 / ENGOT EN-6 / GOG-3031 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY). III
WO42633 (ASTEFANIA) EA PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING  PREOPERATIVE THERAPY. III
ABCSG 50 BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation. III
213831 (ZEST) A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING EFFICACY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY. III
MedOPP240 (METALLICA) STUDY TO EVALUATE THE EFFECT OF METFORMIN IN THE PREVENTION OF HYPERGLYCEMIA IN HR[+]/HER2[-] PIK3CA-MUTATED ADVANCED BREAST CANCER PATIENTS TREATED WITH ALPELISIB PLUS ENDOCRINE THERAPY. THE METALLICA. STUDY II
SOLTI-1905 (ELLIPSE) ELIPSE: Elacestrant en el contexto pre-operatorio, un estudio de ventana de oportunidad. 0
SGNTV-003 /ENGOT-cx12 A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second -or Third- Line Recurrent or Metastatic Cervical Cancer. III
D9673C00007 (DESTINY- Breast12) An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12). III
SOLTI-1805 (TOT-HER3) A window-of-opportunity study of U3-1402, a HER3-targeting antibodydrug conjugate in operable breast cancer according to ERBB3 expression. 0
D967UC00001 (Destiny Breast 09) Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09). III
OZM-058 (NEO) A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer - The NEO trial. II
MedOPP293 (PHERGAIN-2) Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2). II
R2810-ONC-ISA-1981 A PHASE 2 STUDY OF CEMIPLIMAB, AN ANTI-PD-1 MONOCLONAL ANTIBODY, AND ISA101B VACCINE IN PATIENTS WITH RECURRENT/METASTATIC HPV16 CERVICAL CANCER WHO HAVE EXPERIENCED DISEASE PROGRESSION AFTER FIRST LINE CHEMOTHERAPY. II
G1T28-208 (PRESERVE-2) “A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second- Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)” III
WO42133 (TRIO08) A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASEII,NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY,AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLEPLUSPALBOCICLIB FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE UNTREATED EARLY BREAST CANCERA RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASEII,NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY,AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLEPLUSPALBOCICLIB FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE UNTREATED EARLY BREAST CANCER. II
CBYL719K12301/ GEICO 96-O /ENGOT-ov61 Phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC. III
VS-6766-201 (ENGOT-ov60/ncri; GOG-3052) Estudio de fase 2 de VS-6766 (inhibidor dual de RAF/MEK), solo y en combinación con defactinib (inhibidor de FAK) en el cáncer de ovario seroso, de bajo grado y recidivante. II
DS8201-A-U305- DESTINY-Breast05 NSABP B-60- GBG-103- SOLTI-2 A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS  TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY YMPH NODES FOLLOWING NEOADJUVANT THERAPY. III
CO-3810-101(LIO-1) LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor. II

Post authorization & rollover trials: oncology with active recruitment 2021

Trial No. Clinical Trial Phase
IPS-LAN-2018-01 (PANNET) “Efectividad de la dosis de 120 mg de lanreotida en pacientes con tumores neuroendocrinos pancreáticos (TNEP) localmente avanzados o metastásicos en la práctica clínica habitual” IV
20180293 A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Gastric Cancer. IV
TTD-20-01 (RETUD) Estudio epidemiológico observacional multicéntrico descriptivo sobre tumores digestivos. IV
NETFIT WEARABLES EN PACIENTES CON TUMORES NEUROENDOCRINOS GASTROENTEROPANCREATICOS METASTÁSICOS. ESTUDIO NETFIT. IV
BNT000-001 Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during. IV
20190496 An Observational Study in Patients with Locally Advanced or Metastatic Gastric or Gasroesophageal Junction (GEJ) Cancer with Available Test Results for Mucin17 (MUC17) and Claudin-18 Isoform 2 (CLDN18.2) Expression. IV
GETNE-S2109 (NUTRIGETNE) NUTRITIONAL STATUS OF PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR IN SPAIN: NUTRIGETNE. IV
CDRB436X2X02B An open label, multi-center roll-over study to assess longterm safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment. IV
CPDR001X2X01B An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments. IV
TK-SCR-01 Assessing Frequency of HLA-Genotypes and Tumor Antigen Expression in Subjects with Relapsed/Refractory, Advanced-Stage Solid Tumors that may Qualify for T Cell Receptor Based Therapies. IV
BO39633 AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN-LA ROCHE LTD-SPONSORED.  TEZOLIZUMAB STUDY IV
MK-3475-587 A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. IV
B7461027 Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI). IV
CA209-8TT Pan Tumor Study for Long Term Follow-up of Cancer Survivors who have participated in Trials investigating Nivolumab. IV
ART-CAB-2013-01(CATS) Efficacy of Cabazitaxel, Abiraterone and doceTaxel Sequence in men with metastatic castration-resistant prostate cancer: a European, retrospective, observational study (CATS). IV
GEIS 45 "Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de KIT en pacientes con tumores del estroma gastrointestinal (GIST) con respuesta prolongada a Imatinib". IV
SOG-PLA-2016-01 Estudio prospectivo de la utilidad de la biopsia líquida como factor predictor y pronóstico en pacientes con carcinoma urotelial metastásico en progresión tras quimioterapia basada en platino. IV
ISG-GEIS-OS-2 (GEIS 33) Estudio prospectivo observacional de la expresión de ABCB1/P-glicoproteína como factor para la estratificación biológica del osteosarcoma no metastático de las extremidades. IV
GEIS 44 Identificacion de biomarcadores pronósticos en el osteosarcoma de alto grado. IV
F-FR-60000-001 (CASSIOPE) Prospective noninterventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascularendothelial growth factor (VEGF)-targeted therapy. IV
IRONMAN-ES "IRONMAN-ES: Estudio prospectivo observacional de parámetros clinicos y biomarcadores en cáncer de próstata avanzado en hospitales de España". IV
SOGUG-2017-A-IEC REN-7 /SOG-CAB-2019-02 (SRWEC) RETROSPECTIVE STUDY OF CABOZANTINIB IN PATIENTS WITH METASTIC OR UNRESECTABLE RENAL CELL CARCINOMA (RCC) IN SPAIN. SRWEC STUDY (SPANISH REAL WORLD EVIDENCECABOZANTINIB). IV
BAY1841788/20321 An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies. IV
SOG-INM-2020-04 (SOGUG-COVID-19) Estudio Observacional Retrospectivo-Prospectivo en pacientes con tumores genitourinarios que  presentan infección COVID-19 (SOGUG-COVID-19). IV
REVOLUTION Nivolumab in mRCC patients: Treg function, T-cell Access and NK interactions to predict and improve efficacy. IV
BAY 88-8223 / 20510 A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH. IV
BIG 14-01 (AURORA) AURORA: Investigación de las alteraciones moleculares en el cáncer de mama metastásico. IV
OZM-061 (OLALA) Olala: A Retrospective/Prospective Analysis of Characterization of the Long-term Responders on Olaparib in Solid Tumours. IV
GEM-1801 / GEM-IPI-2018-01 ESTUDIO OBSERVACIONAL DESCRIPTIVO SOBRE LAS CARACTERÍSTICAS DEL MELANOMA AVANZADO Y METASTÁSICO EN ESPAÑA. IV
GEICAM 2016-04 AN OBSERVATIONAL, RETROSPECTIVE STUDY ON THE PROGRESS OF BREAST CANCER CASES IN MALES AND THE ASSESSMENT OF RELAPSE RISK THROUGH GENE SEQUENCING. IV
BAY 88-8223/16996 A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride. IV
PUMA-NER-9501 (HER-SEQ) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for Enrollment into Clinical Research Studies of Neratinib. IV
GEM-1901 (BECARE) Retrospective study of adjuvant dabrafenib and trametinib combination in patients with resected melanoma in Spain. IV
GEM 2002 BECARE Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma treated in real life in Spain: a multi-centric, retrospective and non-interventional study. (BECARE). IV
D0817C00098 (ROSY-O) “ROSY-O: A Master, Roll Over StudY for Patients who Have Completed a Previous Oncology Study and Are Judged by the Investigator to Clinically Benefit From Continued Treatment” IV
PALBOSPAIN Análisis observacional del tratamiento con palbociclib en pacientes con cáncer de mama localmente avanzado y/o metastásico RH+/HER2- en primera línea de tratamiento dentro de la práctica clínica habitual. IV

Hematology Clinical Trials (Phase I + Baskets, II-III) with active recruitment 2021

Trial No. Clinical Trial Phase
CC-220-MM-001 A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA I
PCYC-1141-CA (PERSPECTIVE) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma III
X16082 Ensayo de fase Ib/II para evaluar la eficacia y seguridad de ixazomib oral en combinación con sirólimus y tacrólimus como profilaxis de la enfermedad injerto contra huésped crónica. I
NP30179 A MULTICENTER, OPEN-LABEL, PHASE I STUDYTO EVALUATE THE SAFETY,  EFFICACY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF OBINUTUZUMAB (GAZYVA/GAZYVARO) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA I
SHP620-302 (AURORA) A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients III
NP39488 AN OPEN-LABEL, MULTI-CENTER, PHASE IB STUDY OF RO7082859 AND ATEZOLIZUMAB (PLUS A SINGLE PRE-TREATMENT DOSE OF OBINUTUZUMAB) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA I
JCAR017-BCM-001 Ensayo de fase II, multicéntrico, de cohortes múltiples y de un solo brazo para evaluar la eficacia y seguridad de JCAR017 en sujetos adultos con linfoma no Hodgkin de células B agresivo II
UTX-TGR-205 A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma II
GO29781 An open-label, multicenter, phase I/Ib trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with atezolizumab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia I
2102-HEM-101 A Phase 1/2, Multicenter, Open-label study of FT 2102 as a single agent and in combination with Azacitidine or Cytarabine in patiens with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation II
DU176b-A-U157 A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NONRANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS I
63709178AML1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects with Relapsed or Refractory AML. I
AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation III
B0661037 A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS HROMBOEMBOLIC EVENT III
NP40126 A PHASE 1B STUDY EVALUATING RO7082859 IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH RELAPSED REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) OR IN PARTICIPANTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA I
R1979-ONC-1504 A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, AND REGN2810, AN ANTI-PROGRAMMED DEATH-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH B-CELL MALIGNANCIES I
PCI-32765CAN3001 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study. III
ARMY-1 First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia I
DU176b-D-U312 A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE) III
63935937MDS3001 (Imeteslstat) A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment III
17-BI-1206-02 Ensayo clínico de fase I/IIa de BI-1206, un anticuerpo monoclonal contra CD32b (Fc γ RIIB), en combinación con rituximab en personas con linfoma no hodgkiniano de linfocitos B de escasa malignidad que ha recidivado o es resistente al rituximab I
Ponatinib-3001 Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL) III
CL02-ORY-1001AML (ALICE) A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy. II
207497-II (DREAMM6) A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – (DREAMM 6) II
GO40554 A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE UNABLE TO TOLERATE FULL-DOSE CHEMOTHERAPY. I
CC-99282-NHL-001 A PHASE I, MULTI-CENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY NONHODGKIN LYMPHOMAS (R/R NHL) I
GEM2017FIT Tratamiento de inducción con bortezomib, melfalán y prednisona (VMP) seguido de lenalidomida y dexametasona (Rd) frente a carfilzomib, lenalidomida y dexametasona (KRd) más/menos daratumumab, 18 ciclos, seguido de tratamiento de consolidación y mantenimiento con lenalidomida y daratumumab: un ensayo clínico de fase III, multicéntrico, aleatorizado para pacientes adultos mayores, de entre 65 y 80 años, con buen estado general y mieloma múltiple de nuevo diagnóstico. III
BGB-3111-305 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. III
ACE-CL-311/D8221C00001 Ensayo fase 3, aleatorizado, multicéntrico y abierto para comparar la eficacia y seguridad de acalabrutinib (ACP-196) en combinación con venetoclax con y sin obinutuzumab, con la eficacia y seguridad de la quimioinmunoterapia elegida por el investigador en pacientes con leucemia linfocítica crónica sin mutación del(17p) o TP53 no tratada previamente” III
2018-523-00US1 A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma. I
PonaZero Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, who had previously Achieved a Deep Molecular Response with Imatinib. II
MOM-M254-001 A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura II
GC-LTFU-001 Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells II
ME-401-003 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies II
67856633LYM1001 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL I
MT-3724_NHL_001 Safety, Pharmacodynamics and Efficacy of MT- 3724 for the Treatment of Patients with Relapsed or Refractory DLBCL II
ATA129-EBV-302 (TABELECLEUCEL) Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study). III
BST-LT-01 Ensayo clínico fase Ib-II, prospectivo, multicéntrico, abierto y no controlado para evaluar la seguridad y eficacia inmunológica de la infusión de linfocitos T específicos frente a virus a partir del mejor donante disponible en receptores de un trasplante alogénico de progenitores hematopoyéticos II
B1931030 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE. III
CSEG101A2301 “Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de dos dosis de crizanlizumab frente a placebo, con o sin  hidroxiurea/hidroxicarbamida, en pacientes adolescentes y adultos con enfermedad de células falciformes con crisis vaso-oclusivas (STAND)” III
BP41072 AN OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7227166 (A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH BINUTUZUMAB AND IN COMBINATION WITH RO7082859 (CD20-TCB) FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA. I
R1979-ONC-1625 “AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA” II
ADCT-301-201 “A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma” II
DREAMM 7 (GSK 207503) DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of ratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma. III
207499 (DREAMM 8) A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8). III
AFM13-202 (REDIRECT) A phase II Open label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with relapsed or refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REIDRECT) II
CLR_15_03 “A Two-part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia  Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)” II
C0371004 AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF FACTOR IX (FIX) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C£2%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES (NAB) TO ADENO-ASSOCIATED VIRUS VECTOR (AAV)-SPARK100” III
B7841005 (PXL 241325) “An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis” III
AML003/(UYA26495) Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years). with Relapsed/Refractory Acute Myeloid Leukemia (AML) III
CCTL019A2205B Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy. II
QUIWI A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML II
KRT-232-104 "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose  Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)" I
ACE-536-MDS-002 A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions. III
Pevonedistat-1016 “A Phase 1/1b Study of Pevonedistat in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myelogenous Leukemia With Severe Renal Impairment or Mild Hepatic Impairment” I
CCTL019H2301 (BELINDA) Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA) III
INCB01158-206-II A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma II
CSEG101A2203 A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST). II
ACE-536-LTFU-001 A PHASE 3B, OPEN-LABEL, SINGLE-ARM, ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO HAVE PARTICIPATED IN OTHER LUSPATERCEPT (ACE-536) CLINICAL TRIALS. III
C935788-057 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia III
CC-220-MM-001-II A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY AND TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA II
64619178EDI1001-H A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
GLLC-EARLY Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Disease Progression (GELLC-8). III
53718678RSV2005 (FREESIA) A randomized, double blind, placebo-controlled study to evaluate the clinical outcomes, antiviral activity, safety, tolerability, pharmacocinetics, and pharmacocinetics/pharmacodynamics of JNJ-53718678 in adult and adolescent hematopoietic stem cell transplant recipients with respiratory syncytial virus infection of the upper respiratory tract. II
CMBG453B12301 A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2). III
CMBG453E12101 A Phase Ib, multicenter, open-label study of MBG453 and canakinumab or NIS793 in adult patients with lower risk myelodysplastic syndrome I
ARGX-113-1801 “A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia” III
AB15003 A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo un treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap, unresponsive to optimal symptomatic treatment. III
ASPER-III-19-1 A Phase 3, Double-Blind, Multicentric, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability ofltraconazole Dry Powder for Inhalation for the Prevention of Invasive Mould Disease in Patients with Acute Leukaemia and Neutropaenia. III
BGB-3111-306 “A Phase 3 Randomized, Open-Label, Multicenter Study comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma who are ineligible for Stem Cell Transplantation” III
67571244AML1001 A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). I
AUTO4-TL1 A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMENT TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA. I
CO41685 A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF VENETOCLAX AND OBINUTUZUMAB VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION III
RVT-1401-2003 A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia. II
CC-99282-CLL-001 A PHASE 1B, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-99282 IN COMBINATION WITH OBINUTUZUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. I
CJBH492A12101 A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL). I
ACE-LY-312 (D8227C00001) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma III
GCT3009-01 “Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A Firstin-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts” I
GCT3013-01 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma I
CO41942 ESTUDIO DE FASE IB, SIN ENMASCARAMIENTO, MULTICÉNTRICO, NO ALEATORIZADO, PARA EVALUAR LA SEGURIDAD, LA FARMACOCINÉTICA Y LA EFICACIA DE MOSUNETUZUMAB EN COMBINACIÓN CON LENALIDOMIDA, O RO7082859 EN COMBINACIÓN CON LENALIDOMIDA, O RO7082859 EN COMBINACIÓN CON OBINUTUZUMAB MÁS LENALIDOMIDA EN PACIENTES CON LINFOMA FOLICULAR RESISTENTE O RECIDIVANT I
ATA129-EBV-205 An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases I
C3731003 Phase 3, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of PF 07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) III
M13-494 A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14) Positive Relapsed or Refractory Multiple Myeloma III
BAY 94-9027/19764 (JIVI) Post marketing investigation (PMI) to assess safety and efficacy of JIVI (BAY 94-9027) treatment in patients with hemophilia A III
FGCL-4592-082 Phase III trial, investigating efficacy and safety of roxadustat vs. placebo for treatment of anemia with low transfusion burden in patients with low risk MDS III
CLL17 A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL) III
BO42161 “A Phase III, Randomized, Open Label, Active-Controlled, multicenter study evaluating the efficacy and safety of Crovalimab vs Eculizumab in Adult and Adolescent patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) currently treated with compliment inhibitors” III
SRA-MMB-301 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy II
MAA-304 (CRIMSON 1) Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On demand  reatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, With Inhibitors: The Crimson 1 Study. III
WP42004 "ESTUDIO DE FASE I, MULTICÉNTRICO Y ABIERTO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA Y FARMACODINÁMICA DE RO7283420 EN MONOTERAPIA EN LEUCEMIA MIELOIDE AGUDA EN RECAÍDA/RESISTENTE HEMATOLÓGICA Y MOLECULAR" I
CAEL-101-301 “A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis” III
CAEL-101-302 “A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis” III
ALXN-1210-TMA-313 Estudio de fase III, abierto, aleatorizado y multicéntrico de ravulizumab en pacientes adultos y adolescentes que presentan microangiopatía trombótica (MAT) después de un trasplante de células madre hematopoyéticas (TCMH). III
M15-954 A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS). III
74856665AML1001 A Phase 1, First-in-Human, Dose Escalation Study of JNJ-74856665 (DHODH inhibitor) in Participants with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome I
XPORT-DLBCL-030 “A PHASE 2/3, MULTICENTER RANDOMIZED STUDY OF RITUXIMAB-GEMCITABINEDEXAMETHASONE- PLATINUM (R-GDP) WITH OR WITHOUT SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (RR DLBCL)”. II
MOR208C310 “A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, highintermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)” III
75348780LYM1001 “Ensayo fase 1, de primera administración en humanos, de escalado de dosis de JNJ-75348780, un anticuerpo biespecífico anti CD3xCD22, en sujetos con linfoma no Hodking (LNH) y leucemia linfocítica crónica (LLC).” I
ZN-d5-001 “Phase 1 First in Human Dose Escalation Study of ZN d5 as a Single Agent in Subjects with Non-Hodgkin Lymphoma or Acute Myeloid Leukemia” I
M16-109 A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis II
KRT-232-109 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib I
GO41944 “ESTUDIO DE FASE III, ABIERTO, MULTICÉNTRICO Y ALEATORIZADO PARAEVALUAR LA EFICACIA Y LA SEGURIDAD DE GLOFITAMAB COMBINADO CONGEMCITABINA MÁS OXALIPLATINO EN COMPARACIÓN CON  RITUXIMABCOMBINADO CON GEMCITABINA Y OXALIPLATINO EN PACIENTES CONLINFOMA DIFUSO DE CÉLULAS B GRANDES EN RECAÍDA/RESISTENTE AVANZADO IRRESECABLE” III
AUTO1-AL1 “AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA” II
CYTB323A12101 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL. I
64264681LYM1002 A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia I
CL1-64315-004 Estudio de fase I/II, internacional, multicéntrico, abierto, no aleatorizado y no comparativo de S64315, un inhibidor Mcl-1 administrado de forma intravenosa, en combinación con azacitidina, en pacientes con Leucemia Mieloide Aguda I
CCTL019C2202 (BIANCA) Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA). II
BO42203 A PHASE 1B STUDY EVALUATING THE SAFETY, EFFICACY AND PHARMACOKINETICS OF VENETOCLAX IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB (R) AND CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISOLONE (CHP) IN PATIENTS WITH UNTREATED BCL−2 IMMUNOHISTOCHEMISTRY (IHC)-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) I
ADCT-402-103 A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma II
SGN35-031 A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) III
GCT3013-02 A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody® -CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma I
GCT3013-05 A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma III
MK-1026-003 A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies. I
EONHL1-20 A global multicenter phaSe 1/2 trial of EO2463, a novel microbial-derived peptIde therapeutic vaccine, as monotherapy, and in combination with lenaliDomide and rituximab, for treatmeNt of patients with indolEnt Non-Hodgkin's LYmphoma (the "SIDNEY" study). I
4202-HEM-301 Estudio multicéntrico, aleatorizado, controlado con placebo, doble ciego y adaptativo de FT-4202 oral, un activador de la piruvato cinasa en pacientes con anemia drepanocítica4202 II
ALXN2040-PNH-301 “A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)”. III
AG348-C-017/ENERGIZE A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) III
AG348-C-018 (ENERGIZE-T) A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) III
BGB-11417-101 A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies I
SGN35-027 Multiple Part Clinical Trial of Brentuximab Vedotin in classical Hodgkin Lymphoma Subjects. II
KRT-232-113 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis I
INCB 50465-313 “A Phase 3, A Randomized, Double-blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and  Ruxolitinib in Participants with Myelofibrosis” III
INCB 50465-304 A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib III
64407564MMY1001 A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma II
KTE-C19-102 (ZUMA-2) A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2). II
2020-306-GLOB1 “A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations” I
DS3201-A-U202 Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma (Valemetostat tosylate [DS-3201b], an enhancer of zeste homolog [EZH] 1/2 dual inhibitor, for R/R PTCL) II
SNDX-6352-0504 A Phase 2, Openlabel, Randomized, Milticenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses who have Recived at least 2 Lines of Systemic Therapy. II
KRT-232-117 “An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)” I
TL-895-203 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML). I
ENHANCE (5F9009) “ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome.” III
CMBG453F12201 “Estudio de fase Ib/II abierto de sabatolimab como tratamiento para pacientes con leucemia mieloide aguda y enfermedad residual medible después de un trasplante alogénico de células madre” I
INCMOR0208-101 A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Combination Therapy with the anti-CD19 Monoclonal Antibody Tafasitamab and the PI3Kd Inhibitor Parsaclisib in Adult Participants with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia. I
NN7415-4311 (EXPLORER7) Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors. III
54767414ALL2005 (DELPHINUS) A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma II
HOVON-156 AML/ AMLSG 28-18 “Estudio de fase 3 multicéntrico, abierto y aleatorizado de gilteritinib frente a midostaurina, en combinación con un tratamiento de inducción y consolidación, y seguido de un tratamiento de mantenimiento, en pacientes aptos para someterse a una quimioterapia intensiva a los que se les ha diagnosticado recientemente leucemia mielógena aguda (LMA) osíndromes mielodisplásicos con exceso de blastos tipo 2 (SMD EB2) y mutaciones del gen FLT3 ” III
HOVON 150 AML / AMLSG 29-18 A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy III
D8230C00002 A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies I
KRT-232-101 A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment III
68284528MMY3004 (CARTITUDE-5) A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy. III
BO42452 A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD). I
75276617ALE1001 A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia. I
GLA 2017-R2 (Pola-R-ICE) Estudio fase III abierto, prospectivo, para comparar polatuzumab vedotin más rituximab, ifosfamida, carboplatino y etopósido (Pola-R-ICE) y rituximab, ifosfamida, carboplatino y etopósido (R-ICE) solo como terapia de rescate en pacientes con linfoma difuso de célula B grande (LDCBG) primariamente refractarios o en recaída III
BO43243 A PHASE IB OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. I
M16-191 (TRANSFORM-1) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis. III
C1071005 An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab vs Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma. III

Post authorization & rollover trials: hematology with active recruitment 2021

Trial No. Clinical Trial  Phase
FMS-ITK-2016-01 Estudio observacional prospectivo para evaluar la precocidad, estabilidad y profundidad de la respuesta molecular en pacientes recién diagnosticados de leucemia mieloide crónica en fase crónica (LMC-FC) tratados con inhibidores de la actividad tirosina-quinasa (ITK) como tratamiento de primera línea en la práctica clínica IV
GEM-MIE-2014-01 Estudio observacional prospectivo para identificar los aspectos clínicos que conducen a la toma de decisiones terapéuticas en pacientes con mielofibrosis. IV
AG348-C008 Pyruvate Kinase Deficiency Global Longitudinal Registry IV
MSD-CMV-2017-01 ESTUDIO SOBRE LAS COMPLICACIONES CLÍNICAS DIRECTAS E INDIRECTAS DERIVADAS DE LA DETECCIÓN DE LA INFECCIÓN POR CITOMEGALOVIRUS (CMV) EN PACIENTES CON TRASPLANTE ALOGÉNICO DE CÉLULAS PROGENITORAS HEMATOPOYÉTICAS (ALO-TPH). ESTUDIO CMV-ALOTPH IV
CEL-MIE-2016-01 Estudio observacional para valorar la carga de la enfermedad, en términos de Calidad de Vida Relacionada con la Salud y costes sanitarios directos, en pacientes con Mieloma Múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de progenitores hematopoyéticos en España Estudio QoLMMBuS. IV
CC-5013-MDS-010 (216900) (Kaleidoscope) A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide IV
AIE-ART-2016-01 (vertex 2.0) Estudio retrospectivo para evaluar el uso de agonistas de los receptores de trombopoyetina en pacientes adultos con trombocitopenia inmune primaria en España IV
CEL-MIE-2012-01 Estudio observacional post-autorización para evaluar la respuesta de la función renal al tratamiento de pacients con mieloma múltiple en recaída y con aclaramiento de creatinina IV
GCP#04.01.020/030 (Nicord Seguiment) Long Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells IV
BAX-OCT-2011-01/061001 (AHEAD) ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM). IV
GENA-25 Uso práctico de concetrados FVIII de Octafarma en paciente con hemofilia A sin tratamiento previo o mínimamente tratados que se incorporan a un tratamiento clínico rutinario: estudio observacional de la seguridad y eficacia en un entorno real: "Protect Now" IV
JAN-DAR-2018-01 Estudio observacional para describir el impacto de las combinaciones de tratamiento con daratumumab frente a otros tratamientos alternativos en pacientes con mieloma múltiple en recaída / refractario (MMRR). Datos de práctica clínica habitual en España. Estudio GeminiS. IV
INS-FAN-2017-01 (IG1403) A post authorization study to asses the safety and efficacy of Fandhi (Double inactivated human anti-hemophilic factor) sin subjects with Von Willebrand disease. IV
GEM-DAR-2018-01 Treatment with Daratumumab in relapsed / refractory Multiple Myeloma patients in clinical care practice in Catalonia. A retrospective study IV
ATA129-RS002 A Retrospective Study of Treatment Outcomes in Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplant or Solid Organ Transplant who have Failed Rituximab or Rituximab Plus Chemotherapy. IV
DNO-IBR-2018-01 Virología e inmunología de la infección por el citomegalovirus (CMV) en el paciente con neoplasias hematológicas en la era de las nuevas bioterapias. IV
Sobi.Elocta-005 (A-MORE) Estudio observacional, multicéntrico de 48 meses de seguimiento para evaluar la eficacia a largo plazo de Elocta en la salud articular. IV
C-935788-058 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia IV
54767414MMY4024 / JAN-DAR-2019-02 Estudio observacional para describir la repercusión de los anticuerpos monoclonales como tratamiento de primera línea frente a otros regímenes estándar en pacientes con mieloma múltiple de nuevo diagnóstico que no sean candidatos a trasplante. Datos de práctica clínica habitual en España. IV
CEL-BEN-2019-01 (MYHRAI) Real-world trends in clinical management of Relapsed/Refractory Multiple Myeloma (RRMM) patients who have received at least 2 prior anti-myeloma regimens: results from exploring electronic health records (EHR) with artificial intelligence (AI) – ‘’MYHRAI study’’ IV
KTE-iNHL-RW2020 Real-World Response/Survival and Treatment Patterns among Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in USA, UK, France, and Spain Oncology Practices. IV
ML40944 (HEMOLIFE) ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA CALIDAD DE VIDA DE PACIENTES CON HEMOFILIA A SIN INHIBIDORES. IV
TAK620-5002 “Multinational CMV Outcomes, Treatment Patterns and Healthcare Resource Utilization Study (OTUS) following hematopoietic Stem Cell Transplant (HSCT)”. IV
BAY-DAM-2019-01 (HEM-POWR) HEM-POWR: Estudio observacional para evaluar la eficacia y la seguridad del tratamiento con damoctocog alfa pegol en la vida real en pacientes con hemofilia A tratados previamente. IV
MOTIVATE “MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial” IV
TAK-660-403 Evaluation of long-term safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in patients with haemophilia A – An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS). IV
TAK-705-3003 Natural History and Treatment Outcomes of Congenital and Immune Thrombotic Thrombocytopenic Purpura: a Retrospective Chart Review Study IV
Sobi.Alprolix-002 (B-MORE) Estudio observacional y multicéntrico de 48 meses para evaluar la eficacia a largo plazo de Elocta en la salud articular. IV

Early Clinical Drug Development

Code Clinical Trial Title Phase
CLGK974X2101 A Phase I, open-label, dose escalation study of oral LGK974 in patients with melanoma and breast cancer. I
B7461001 PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS. I
H9H-MC-JBAH Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination with Lomustine in Patients with Recurrent Malignant Glioma I
TPU-TAS-120-101 A DOSE-FINDING PHASE 1 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH OR WITHOUT FIBROBLAST GROWTH FACTOR/RECEPTOR (FGF/FGFR)-RELATED ABNORMALITIES FOLLOWED BY A PHASE 2 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR MULTIPLE MYELOMA WITH FGF/FGFR-RELATED ABNORMALITIES I
TED13751 A first-in-human study for the evaluation of the safety, pharmacokinetics and antitumor activity of SAR408701 in patients with advanced solid tumors. I
CINC280X2105C A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR
mutated non-small cell lung cancer
I
MCLA128-CL-01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors II
CLDK378A2120C A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) I
CPDR001X2101-II Estudio de fase I/II, abierto, multicéntrico, de la eficacia y la seguridad de PDR001 administrado en pacientes con tumores malignos avanzados. II
CA209-358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors. I
CA224-020 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody  Nivolumab, BMS-936558) in Advanced Solid Tumors I
BAY 2757556 (LOXO-TRK-15002) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors II
B9991005 A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. I
MK-3475-158 Ensayo clínico de evaluación de biomarcadores predictivos con pembrolizumab (MK-3475) en pacientes con tumores sólidos avanzados (KEYNOTE 158) II
I5B-MC-JGDL A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma I
MM-398-07-02-03 A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma. I
PCYC-1128-CA A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors I
EMR200647-001 (TRAP001) Ensayo de fase I, abierto, con dosis múltiples ascendentes, para investigar la seguridad, tolerabilidad, farmacocinética, y actividad biológica y clínica de MSB0011359C en sujetos con tumores sólidos metastásicos o localmente avanzados y expansión a indicaciones seleccionadas I
CC-90010-ST-001 A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90010 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY NON-HODGKIN?S LYMPHOMAS I
CLXH254X2101 A phase I dose finding study of oral LXH254 in adult patients with advanced solid tumors harboring MAPK pathway alterations. I
CPDR001X2102 Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001
in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) .
I
I8X-MC-JECA A Phase 1 Study of LY3200882 in Patients with Solid Tumors. I
GO30103 (FELIX) "A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS" I
CFAZ053X2101 A phase I, open-label, multi-center dose escalation study of FAZ053 as single agent and in combination with PDR001 in
adult patients with advanced malignancies.
I
H3B-6527-G000-101 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma I
CA017-003-II A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors. II
204691( ICOS ) A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects
with Selected Advanced Solid Tumors.
I
RXDX-101-02 (STARTRK-2) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. II
63723283LUC1001 A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers. I
WIN001 (SPRING) Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination. I
1280.18 An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally
advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts.
I
D419NC00001 A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors. I
GO39374 A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF GDC-0077 AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE AND TARGETED THERAPIES IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE-RECEPTOR POSITIVE BREAST CANCER
I
CPDR001C2101 Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1unselected, metastatic NSCLC patients I
BAY94-9343/15834 Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with mesothelin expressing advanced or recurrent malignancies. I
VHIO-PBF-999-01 "Phase I/Ib trial of single agent PBF-999 in solid tumour advanced cancer" I
CTNO155X2101 An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors I
MK-4280-001 "A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors" I
PM14-A-001-17 Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors I
4010-01-001 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors I
CP-MGA012-01 A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors. I
W00101 IV 1 01 Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors International, multicenter, open label study. I
CNIR178X2201 A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma. II
WO39608 (MORPHEO 1) A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER). I
CB103-C-101 A PHASE I/IIA, MULTI-CENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY WITH EXPANSION ARMS TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CB-103 ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL  ALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY . I
CLHC165X2101 A Phase I/Ib, open-label, multi-center dose-escalation and dose-expansion study of the safety and tolerability of intratumorally administered LHC165 single agent and in combination with PDR001 in patients with advanced malignancies. I
ARRAY-162-202 An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer with RAS Mutation I
BLU-667-1101 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors. I
CDRB436X2X02B An open label, multi-center roll-over study to assess longterm safety in patients who are ongoing or have completed
a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment.
ROLLOVER
C0541001 A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS. I
BAY 1163877 / 19131 An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. I
64091742PCR2002 A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer. I
BO39610 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE  IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MORPHEUS-LUNG). I
AG270-C-001 A Phase 1 Study of AG-270 in the Treatment of Subjects with Advanced Solid Tumors or Lymphoma with Homozygous Deletion of MTAP. I
1401-0001 An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 905677 administered intravenously in patients with advanced solid tumours. I
GO39733 A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. I
XL184-021 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
B9991023 A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES. I
BP40087 AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7122290, A FIBROBLAST ACTIVATION
PROTEIN-a (FAP) TARGETED 4-1BB LIGAND (CD137L), WITH OR WITHOUT OBINUTUZUMAB PRE-TREATMENT, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB FOLLOWED BY TUMOR SPECIFIC EXPANSION COHORT(S).
I
GO39932 "A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC 9545 Alone or In Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer" I
CO40115 "A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MORPHEUS TNBC)" I
IO102-012(KN-764) An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer. I
CA022-001 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. I
MEN1611-01(B PRECISE 01) OPEN-LABEL, MULTICENTER, PHASE IB DOSE-ESCALATION STUDY OF MEN1611, A PI3K INHIBITOR COMBINED WITH TRASTUZUMAB ± FULVESTRANT, IN SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADVANCED) OR METASTATIC (A/M) BREAST CANCER PROGRESSED TO ANTI-HER2 BASED THERAPY . I
LOXO-EXT-17005 A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion
Cancers.
I
BP40234 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1), ADMINISTERED INTRAVENOUSLY, IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. II
LOXO-RET-17001 "A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medularry Thyroid Cancer, and Other Tunors with Increased RET Activity". I
GCT1029-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors. I
BGB-290-103 A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors. I
204686 "A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors" I
MCLA-158-CL01 Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors. I
64619178EDI1001 A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects with Advanced Cancers. I
Brigatinib-1001 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. I
CC-90011-ST-001 A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-90011 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN’S LYMPHOMAS. I
IOV-COM-202 A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors. II
BP40657 A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER. I
J1F-MC-JZFA A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors. I
VHIO17002 (MO39164) Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours. II
D8530C00001 A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast CancerA Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer. I
C2321001 A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL). I
ACT15377 Estudio en fase 1/2, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de isatuximab (SAR650984) en combinación con atezolizumab o solo isatuximab en pacientes con enfermedades malignas avanzadas I
INCB01158-101 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with vanced/Metastatic Solid Tumors. I
2102-ONC-102 A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation. I
GEIS 58 (OLATRASTS) "Ensayo clínico de fase I con Olaratumab más Trabectedina en pacientes con sarcoma de tejidos blandos avanzado" I
CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H). II
CO40939 A PHASE Ib, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMAKOKINETICS OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
CADPT01A12101C A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer. I
YO40482 A PHASE Ib STUDY OF COBIMETINIB ADMINISTERED IN COMBINATION WITH NIRAPARIB, WITH OR WITHOUT ATEZOLIZUMAB, TO PATIENTS WITH ADVANCED PLATINUM-SENSITIVE OVARIAN CANCER. I
MK-7339-002 A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer. II
SGNTV-001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. II
61186372EDI1001 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer. I
B9991032 A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS. II
ICO-VCN-H&N-2018 A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck. I
WO39613 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC). I
A206T-G01-001 (PROTER) A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic
treatment.
I
GCT1046-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects
with malignant solid tumors.
I
BP40657-III A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN  ATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER III
CP-MGD013-01 A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms. I
BO40933 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IPATASERTIB IN COMBINATION WITH RUCAPARIB IN PATIENTS WITH ADVANCED BREAST, OVARIAN, OR PROSTATE CANCER. I
ZEN003694-004 A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer. I
D7980C00001 (MEDI5752) A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics
Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors.
I
20140318 (MASTERKEY-318) A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318). II
8374-CL-0101 A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors. I
NBTXR3-102 ESTUDIO DE FASE I DE AUMENTO ESCALONADO/AMPLIACIÓN DE LA DOSIS DE NBTXR3 ACTIVADO MEDIANTE RADIOTERAPIA DE INTENSIDAD MODULADA EN PACIENTES CON CARCINOMA DE CÉLULAS ESCAMOSAS LOCALMENTE AVANZADO EN LA CAVIDAD BUCAL O LA OROFARINGE. I
Debio 1143-106 SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. II
SC103 A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. I
XL184-021 (PULMON) A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors. I
BP41054 AN OPEN-LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAP), IN COMBINATION WITH PEMBROLIZUMAB (ANTI-PD-1), IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED AND/OR METASTATIC MELANOMA. I
208850 (STING) A Phase I First Time in Human Open Label Study of GSK3745417 administered with and without Anticancer Agents in Participants with Advanced Solid Tumors. I
TCD14678 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination
with cemiplimab in adult patients with advanced solid tumors.
I
CLXH254X2102 A Phase Ib, open-label, multicenter study of oral LXH254- centric combinations in adult patients with advanced or
metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer or NRAS mutant melanoma.
I
CTNO155B12101 A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155
in combination with spartalizumab or ribociclib in selected malignancies.
I
207675 A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL. I
CP-MGC018-01 A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation of Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) alone and in combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors. I
M19-037 A Phase 1, Multi-Center, Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Pharmacokinetics of ABBV-927 and ABBV-368 with and without ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumor. I
LOXO-RET-18037 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201). I
1336-0011 An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability,
pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
I
CL1-95012-001 “Estudio de primera administración en humanos de fase I/II, abierto, multicéntrico, de escalada de dosis y expansión con PRS-344/S095012 en pacientes con tumores sólidos” I
1426-0001 Phase I, first in human trial evaluating BI 1387446 alone and in combination with BI 754091 in solid tumors. I
ASTX029-01 A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors. I
SGN228-001 A phase 1 study of SGN-CD228A in subjects with select advanced solid tumors. I
MS201922-0001 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors. I
42756493CAN2002/ODIN (RAGNAR) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations. II
NP40435 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7121661, A PD-1/TIM-3 BISPECIFIC  NTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
CNTO1959COR1001 A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the
Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis.
I
20180290 A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects with MUC17-Positive Gastric and Gastroesophageal Junction Cancer. I
CPDR001X2X01B An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who
have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments.
ROLLOVER
GCT1021-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. I
U31402-A-U102 A MULTICENTER, OPEN-LABEL PHASE 1 STUDY OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE NON-SMALL CELL LUNG CANCER.
I
NP41300 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE SAFETY/TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
CNIZ985B12101 A Phase I/Ib Study of Subcutaneous Recombinant NIZ985 ((het-IL-15) (IL-15/sIL-15Rα)) in combination with Spartalizumab in adults with check point inhibitor (CPI) relapsed advanced malignancies. I
SOLTI-1507 (IPATHER) A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PI3KCA-mutant, HER2-positive locally advanced or metastatic breast cancer (IPATHER) I
INCB 54828-207 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). II
2455-002 An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastatic Urothelial Carcinoma. I
WP41188 AN OPEN LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION, PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF RO7296682, A CD25-TARGETING, T-REGULATORY CELL DEPLETING ANTIBODY IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS I
SL01-DEL-101 Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas. I
WP41377 A FIRST IN HUMAN, OPEN LABEL, DOSE ESCALATION PHASE I STUDY EVALUATING SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ACTIVITY PROFILE OF SINGLE AGENT RO7119929 (TLR7 AGONIST 4 ASIP) ADMINISTERED ORALLY TO PARTICIPANTS WITH UNRESECTABLE ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA, BILIARY TRACT CANCER, OR SOLID TUMORS WITH PREDOMINANTLY HEPATIC METASTASES. I
73841937NSC2001 A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC). I
CKAZ954A12101 A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors. I
EOGBM1-18 A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents with ProgrEssive Glioblastoma (Rosalie study). I
AFM24-101 A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers. I
BAY88-8223/19781 An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer. I
CV-8102-008 Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. I
1412-0001 A first-in-human phase Ia/b, open label, multicentre, dose escalation study of BI 905711 in patients with advanced gastrointestinal cancers. I
IMC-C103C-101 A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer. I
J2J-MC-JZLA A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer. I
208471 A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer. I
CC-90011-SCLC-001 A PHASE 1B, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF CC-90011 GIVEN IN COMBINATION WITH CISPLATIN AND ETOPOSIDE TO SUBJECTS WITH FIRST LINE, EXTENSIVE STAGE SMALL CELL LUNG CANCER. I
2SMALL Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy. I
GCT1044-01 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumours. I
EOADR1-19 (SPENCER) A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma. I
GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS
OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH
TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS.
I
CO41863 A PHASE Ib/II, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTANSINE (T-DM1) IN PREVIOUSLY TREATED HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS. I
CC-90010-GBM-002 A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90010 IN COMBINATION WITH TEMOZOLOMIDE
WITH OR WITHOUT RADIATION THERAPY IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.
I
208750 Seguimiento a largo plazo de los participantes expuestos a GSK3377794 (NY-ESO-1c259 T), un receptor de linfocitos T específicos de NY-ESO-1 modificado genéticamente. I
BP41628 AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSEESCALATION AND EXTENSION, PHASE IA/IB STUDY TO
EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
I
BNT411-01 Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer
(ES-SCLC).
I
CO41792 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. I
ODO-TE-S101 An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food,Itraconazole,and Rifampinon Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors. I
1438-0001 A First–in-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3. I
M19-611 A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer. I
4020-01-001 (AMBER) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER). I
ICT01-101 A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study). I
DCC-3014-01-001 A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors. I
D6770C00001 Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumors. I
Uni-Koeln-1784 (EATON) An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generationEGFR TKI therapy. I
DEBIO 1143-106-II SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial. A dose-optimization, exploratory phase Ib/II study to assess safety and efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) mimetic Debio 1143, when given in combination with the anti-PD-1 antibody nivolumab in patients with specific solid tumors who have progressed during or immediately after anti-PD-1/PD-L1 treatment. II
70218902EDI1001 A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors. I
Debio 0123-101 A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors. I
20180292 A Global Phase 1 Study Evaluating the Safety,Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. I
CBLZ945X2101 A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors. I
MEN1611-02 (C-PRECISE-01) OPEN-LABEL,MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CAMUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR CONTAINING REGIMENS. I
V937-013 Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors. I
GO41751 A PHASE I, OPEN-LABEL, DOSE-ESCALATION PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER. I
LOXO-IDH-20002 A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 R132 Mutations. I
GCT1042-01 A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects with Malignant Solid Tumors. I
NOCANTHER A feasibility clinical investigation of intratumoral injection of magnetic nanoparticles associated to hyperthermia treatment
in locally advanced pancreatic cancer.
I
D967VC00001(DESTINY-PanTumor02) Phase 2, Multicentre, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors . II
PM1183-A-017-20 An Open-Label, Multicenter, Pharmacokinetic Study of Lurbinectedin in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment. I
AFM24-101-II A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers. II
D967MC00001 (DESTINY) Phase II, multicenter, open-label study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of unresectable and/or metastatic solid tumors harboring HER2 activating mutations regardless of tumor histology. II
CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers. I
SGNTGT-001 A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies. I
73841937NSC1001 An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer. I
D967LC00001(DESTINY 3) A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and
Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03).
I
213152 A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer with Disease Progression or Recurrence Following Treatment with a Platinun agent. I
BT8009-100 (BICYCLE) Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies. I
ACT16432 Open-label, multi-cohort, Phase 2 trial, evaluating the efficacy and safety of SAR408701 in patients with CEACAM5-positive advanced solid tumors. II
CADPT01C12101 A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer. I
CJDQ443A12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. I
TAS-120-202 A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations. II
GO42144 A PHASE I DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC 6036 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION. I
ABT-C11-2020 A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. I
BP42169 AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7293583, A TYRP1-TARGETING CD3 T-CELL ENGAGER, IN PARTICIPANTS WITH METASTATIC MELANOMA. I
BP42595 AN OPEN-LABEL, MULTICENTER PHASE 1b STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7296682 IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
DZB-CS-202 (BASILEA) Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03). I
SGNB6A-001 A Phase 1 Study of SGN-B6A in Advanced Solid Tumors. I
CA030-001 A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors. II
MS200647_0046 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer. I
R6569-ONC-1933 A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies. I
D9720C00001(PETRA) A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5305 monotherapy and in combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies. I
BP42675 AN OPEN LABEL, MULTICENTER, PHASE IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI TUMOR ACTIVITY OF CIBISATAMAB IN COMBINATION WITH RO7122290, A FIBROBLAST ACTIVATION PROTEIN A (FAP) TARGETED 4 1BB LIGAND (CD137L), WITH OBINUTUZUMAB PRE TREATMENT, IN PARTICIPANTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABLE COLORECTAL ADENOCARCINOMA WITH HIGH CEACAM5 EXPRESSION. I
OMO-103-01(OMOMYC) A Phase 1/2 Study to evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the Myc Inhibitor OMO-103 administered intravenously in Patients with Advanced Solid Tumours. I
2020-306-GLOB2 MULTICENTER, OPEN-LABEL PHASE I STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-306 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.
WITH IDH MUTATIONS
I
CTL-002-001 A PHASE I, FIRST IN HUMAN, TWO PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT-INHIBITOR IN SUBJECTS WITH ADVANCED STAGE, RELAPSED/REFRACTORY SOLID TUMORS. I
FS222-19101 (F-STAR) A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects with Advanced Malignancies. I
CDKY709A12101C A phase I, open-label, multi-center, study of DKY709 as a single agent and in combination with spartalizumab in patients with advanced solid tumors, I
1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit. I
20180143 A Phase 1 Study to Evaluate Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors. I
CTMX-M-2029-001 (PROCLAIM-CX-2029) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or
Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029).
I
CO42867 Phase 1b/II umbrella, adaptive design study
The first cohort of the new Breast Cancer study will target 2L or 3L metastatic or inoperable locally advanced ER+ Breast Cancer patients who had disease progression during or following treatment with a CDK4/6i.
I
AGI-134.FIM.101 A PHASE I/IIA, MULTICENTRE, TWO-PARTS, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF AGI-134 GIVEN IN UNRESECTABLE/METASTATIC SOLID TUMOURS I
VHIO20001 (NEXTGEN-TIL-ACT) A Phase I study to assess the safety and tolerability of ex vivo neoantigen-selected Tumor-infiltrating Lymphocytes (TILs) in advanced epithelial tumors and refractory melanoma. I
1472-0001 A Phase Ia/Ib, open-label, multicentredose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumoursexpressing KRAS G12C mutation. I
20180144 A Phase 1 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients with Advanced Solid Tumors. I
BNT151-01 Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT151 as a monotherapy and in combination with other anti-cancer agents in patients with solid tumors. I
20160323 (AMG757) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer. I
SOLTI-1904 (ACROPOLI) EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high
mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial).
II
D933IC00001(MAGELLAN) A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN). I
D9570C00001 A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, anti-TIM-3 and anti PD-1 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors . I
SGNSTNV-001 A Phase 1 Study of SGN-STNV in Advanced Solid Tumors. I
WP42627 AN OPEN LABEL, MULTICENTER, DOSE-ESCALATION AND EXPANSION, PHASE I STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND ANTI-TUMOR ACTIVITY OF RO7300490, A FIBROBLAST ACTIVATION PROTEIN-á (FAP) TARGETED CD40 AGONIST, AS SINGLE AGENT OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. I
NLM-2020-01(NELUM-NLM) Phase Ib/IIa Study to evaluate safety and efficacy of Priming Treatment with the Hedgehog Inhibitor NLM-001 Prior to Chemotherapy (Gemcitabine and Nab-Paclitaxel) plus AGEN 1884 as First Line treatment in Patients with Advanced Pancreatic Cancer. I
Sym021-02 An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD-1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies. I
M20-111 A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 monotherapy and combined with docetaxel in adult subjects with relapsed and refractory solid tumors. I
BO41932 TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL. II
ACT16845 Estudio de fase 2 no aleatorizado, abierto, multicéntrico y de múltiples cohortes que evalúa el beneficio clínico de SAR444245 (THOR-707) en combinación con cemiplimab para el tratamiento de participantes con cáncer avanzado de piel irresecable o metastásico I
MK-6482-016 An Open-label, Multicenter, Phase 2 Study of Pembrolizumab Plus Lenvatinib in Combination With MK-6482 in Multiple Solid Tumors. II
CIAG933A12101 “Estudio de fase I, multicéntrico y abierto de IAG933 oral en pacientes adultos con mesotelioma avanzado y otros tumores sólidos” I
CO42800 "A PHASE IB, OPEN-LABEL, DOSE-ESCALATION AND DOSEEXPANSION
STUDY EVALUATING THE SAFETY,
TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY
ANTI-TUMOR ACTIVITY OF INAVOLISIB IN COMBINATION WITH
PACLITAXEL AND WITH OR WITHOUT TARGETED THERAPIES
IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC
SOLID TUMORS".
I
CAN04CLIN003 A PHASE 1B DOSE ESCALATION AND EXPANSION STUDY OF CAN04, A MONOCLONAL ANTIBODY TARGETING IL1RAP, IN COMBINATION WITH MODIFIED FOLFIRINOX IN SUBJECTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA. I
MK-3475-B98  (KEYNOTE-B98) A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy. I
D9950C00001 A Phase I First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701
Administered Intravenously as Monotherapy and in Combination With Durvalumab (MEDI4736) in Participants With Advanced Solid Tumours.
I
WO42758 (INTRINSIC) A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC). I
DS1062-A-U102 (Tropion- Lung02) “Phase 1b, Multicenter, Open-label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Pembrolizumab with or without Platinum Chemotherapy in Subjects with Advanced or Metastatic NonSmall Cell Lung Cancer (Tropion-Lung02)” I
EZH-108 A PHASE I, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A
STRONG CYP3A4 INHIBITOR ON THE STEADYSTATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF  AZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES.
I
20190136 A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects with Advanced Solid Tumors. I
78306358STM1001 A Phase 1, First-in-Human, Dose Escalation Study of JNJ-78306358 in Participants with Advanced Stage Solid Tumors. I
CAN04CLIN004 Phase 1/2 study of CAN04 (a fully humanized monoclonal antibody against L1RAP) in combination with different chemotherapy regimens in patients with advanced solid tumors. I
ANV419-001 ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and
Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors.
I
1463-0001 Phase I dose-finding study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers. I
INCB 106385-102 A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors. I
GEIS-67 (SeliSarc) Ensayo clínico aleatorizado fase I/II de selinexor más gemcitabina en determinados sarcomas de partes blandas y osteosarcomas avanzados. I
M20-732 A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination with Modified FOLFIRINOX (mFFX) With or Without Budigalimab compared to mFFX in Subjects with Untreated Metastatic Pancreatic Adenocarcinoma. I
AFM24-102 A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR expressing Cancers I
TK-SCR-01 Assessing Frequency of HLA-Genotypes and Tumor Antigen Expression in Subjects with Relapsed/Refractory, Advanced-Stage Solid Tumors that may Qualify for T Cell Receptor Based Therapies. EPA-OD
STRO-002-GM1 A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers. I
20140318 (MASTERKEY-318) A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination with Systemic Pembrolizumab (MASTERKEY-318). I
1403-0001 A phase Ia/Ib, open labeA phase Ia/Ib, open label, multicenter, dose-escalation study of
BI 907828 in patients with advanced or metastatic solid tumorsl, multicenter, dose-escalation stud
I
D9720C00001(PETRA) A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5305 monotherapy and in combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies. II
D967LC00001(DESTINY 3) A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and
Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03).
II